Cerevel licenses several CNS assets from Pfizer concurrent with spin-off as independent company
Executive Summary
Concurrent with being spun-off from Pfizer Inc. and Bain Capital, Boston-based Cerevel Therapeutics LLC has in-licensed several neuroscience assets from the Big Pharma.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
- Reverse Licensing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice